Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQH3906 in Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
NCT06754891Phase 1Recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Jan 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TQH3906 in ulcerative colitis (UC) and Crohn's disease (3 arms), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Adverse event rate at 16 weeks, Clinical remission rate: Ulcerative colitis (UC): Mayo score at 8 weeks and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
TQH3906
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT06754891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06754891.